title: [Mycobacterium massiliense bone infection].
authors.forename: R
authors.initials: R
authors.lastname: Breda
authors.forename: F
authors.initials: F
authors.lastname: Janvier
authors.forename: C
authors.initials: C
authors.lastname: Macnab
authors.forename: S
authors.initials: S
authors.lastname: Rigal
mesh_terms: D002921:Cicatrix / Q000382:microbiology / Q000601:surgery; D017291:Clarithromycin / Q000627:therapeutic use; D003646:Debridement; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004198:Disease Susceptibility; D005264:Femoral Fractures / Q000601:surgery*; D005593:Fracture Fixation, Internal; D005596:Fractures, Closed / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D009170:Nontuberculous Mycobacteria / Q000302:isolation & purification*; D010019:Osteomyelitis / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology* / Q000601:surgery; D010027:Osteotomy; D021521:Ribotyping; D012293:Rifampin / Q000008:administration & dosage; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D014640:Vancomycin; D017291:Clarithromycin; D012293:Rifampin